The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.875
Bid: 9.50
Ask: 10.25
Change: 0.175 (1.80%)
Spread: 0.75 (7.895%)
Open: 9.875
High: 9.875
Low: 9.875
Prev. Close: 9.70
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Somero upbeat after strong year; Scancell in profit

Wed, 26th Jan 2022 20:18

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Somero Enterprises Inc - Fort Myers, Florida-based concrete levelling equipment company - Reports "strong, profitable trading" and now expects 2021 revenue, earnings before interest, tax, depreciation and amortisation, and year-end cash ahead of guidance. Expects revenue of around USD133.0 million versus guidance of USD130.0 million, adjusted Ebitda of USD48.0 million, up 83% on 2020 and ahead of guidance at USD45.0 million, and year-end cash of USD42.0 million, versus guidance of USD39.0 million. Expects 2022 will be "highly profitable year".

----------

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Reports pretax profit of GBP2.5 million for six months to October 31, swinging from loss of GBP4.4 million year-on-year. Firm gets boost from GBP7.2 million gain on substantial modification of convertible loan notes. Says firm is well-funded and strong cash position should allow it to "pursue multiple clinical programmes". "The funding received in the last financial year will also provide the company with further flexibility regarding the development plans for its existing therapies, to ensure both optimal development and commercialisation strategies can be pursued, and to limit the potential impact on the company of economic pressures caused by Covid-19," it says.

----------

Hargreaves Services PLC - Durham, England-based services to industrial and property sectors - Revenue for six months to November 30 falls to GBP76.1 million from GBP92.0 million a year ago but pretax profit jumps to GBP10.4 million from GBP1.1 million on boost from share of profit in joint ventures. Says revenue reduced as expected following exit from coal business. Interim dividend lifted to 2.8p from 2.7p. "The German joint venture continues to deliver substantial profits and our balance sheet is strong with no bank debt. The board has increased its expectations for financial performance in the current and future years materially and I look forward to reporting further progress in due course," says Chair Roger McDowell.

----------

Henderson Smaller Cos Investment Trust PLC - invests in medium and small UK companies - Net asset value total return minus 2.1% for six months to November-end, faring better than benchmark which falls 2.8%. NAV per share stands at 1,286.2p at November 30, down from 1,329.1p at May 31 but up from 1,017.4p a year ago. Maintains interim dividend at 7.0p per share. "During the six months to 30 November 2021, UK equity markets were broadly flat, although smaller companies underperformed larger stocks as investor sentiment shifted from growth-oriented companies to those with more value type characteristics," firm notes.

----------

Rockpool Acquisitions PLC - special purpose acquisition company - Reports pretax loss of GBP13,004 million for six months to end of September, widened from GBP5,887 a year ago. No revenue recorded in either period. Says continued hunt for acquisition in the period and remains confident in a transaction materialising "delay in and the anticipated termination of the transaction previously proposed with Greenview Gas". Plans to apply to UK Financial Conduct Authority to have share suspension lifted as soon as transaction with Greenview is terminated, expected to happen by March-end.

----------

Okyo Pharma Ltd - London-headquartered biotechnology company - Reports loss of GBP2.0 million for six months to September-end, widened from GBP485,960 a year ago. Total assets down to GBP4.2 million from GBP5.1 million at March 31. Firm says it needs to raise additional investment in order to meet liabilities over next 12 months. "Consequently, in the opinion of the directors there is a material uncertainty that may cause significant doubt about the group's ability to continue as a going concern. Despite this material uncertainty, the directors conclude that it is appropriate to continue to adopt the going concern basis of accounting," firm says.

----------

Chrysalis Investments Ltd - investor in technology and finance startups - Net asset value per share rises 57% to 251.96p at end of September from 160.97p a year ago. Says it achieved further diversification during the year and added five new investments, taking portfolio to 15 holdings. "The board is delighted with the performance of the investment team, to which further resource was added post year end to bolster the Finance and ESG functions. In the space of three years, the team has built a unique platform by which ordinary investors can access the opportunities available in the late-stage private market. With interest in private investing growing, I believe Chrysalis is extremely well placed to continue its development," says Chair Andrew Haining.

----------

Warehouse REIT PLC - real estate investment trust focused on warehouse assets - Has completed 12 new lettings and 10 lease renewals since October 1, with transactions completed at 11% ahead of March estimated rental value, generating GBP900,000 per year of contracted rent. Rent collection has remained strong with over 98% of rent due for the financial year ending March 31 collected. Affirms near-term intention to move to London's Main Market.

----------

Bushveld Minerals Ltd - South African vanadium producer - Reports 2021 production of 3,592 metric tonnes of vanadium, at the upper end of guidance but slightly below 2020's 3,631 mtV. Sales of 3,314 mtV in year were "impacted by challenges in international logistics channels arising from Covid-19, the unrest in South Africa and disruptions at local ports in July and August". Expects production of between 4,200 mtV and 4,400 mtV in 2022. "We look forward to the year ahead on the back of the strong foundation we have set and the production growth mostly attributable to the Kiln 3 commissioning in 2022. Production growth is key to unit cost reduction and margin expansion, as reflected in the guidance for 2022," says Chief Executive Fortune Mojapelo.

----------

Medica Group PLC - Hastings, England-based provider of medical imaging services - Shows "robust recovery" in 2021 and expects revenue for year to be GBP61.9 million, up 68% on the year before and 33% higher than 2019. "An increase in gross margin compared with 2020, together with careful control of costs during the pandemic means that underlying profit for the year is expected to be ahead of market expectations," it says. Ends year with net cash of GBP3.6 million after starting with debt of GBP3.9 million. Notes risks from new Covid variants, but is confident clients have now developed strategies to minimise hospital disruption. "Building on a successful 2021 and our recent acquisitions, we believe Medica is well positioned to take advantage of future opportunities," it says.

----------

Revolution Beauty Group PLC - AIM-listed beauty products retailer - Says sales over peak Christmas trading period up 41% year-on-year on underlying basis and retains guidance for full-year. "As we look forward, our growth in our direct to consumer business coupled with our successful retail expansion into the UK and the US provides strong momentum for the business. We look forward to updating the market with our full year results later in the year," says Chief Executive & Co-Founder Adam Minto.

----------

Dianomi PLC - London-based digital advertiser - Says revenue growth in excess of 25% in 2021, while adjusted Ebitda is seen slightly ahead of market expectations. Says year was "excellent". "Demand from both advertisers and publishers has been strong and the second six months of the year saw further new advertisers and publishers 'go live' on Dianomi's platform, as well as growth within the existing publisher and advertiser base," firm says.

----------

Restore PLC- Redhill, England-based document management and IT recycling business - Says 2021 performance was ahead of expectations after strong final quarter. Expects to report "record" levels of revenue and underlying profit . Says annualised revenue run rate has expanded to GBP255 million, up 18% on pre-pandemic levels. "Trading since the end of FY21 has followed the same positive trajectory seen in December and the board remain very confident in delivering further significant progress in 2022," company adds.

----------

Anpario PLC - Nottingham, England-based manufacturer of animal feed additives - Earnings for 2021 to be in line with current market expectations with full year sales to be not less than GBP33 million. Says operating performance strong despite "number of challenges" in global markets and supply chains due to pandemic. "We have continued to experience increased logistics and raw material price inflation, the cost of which is being passed on through sales price increases. We are seeing some encouraging signs that cost price inflation has begun to stabilise and the improving international travel situation will help our sales teams drive new business development initiatives," firm adds.

----------

Flowtech Fluidpower PLC - supplier of technical fluid power products - Expects to report 2021 revenue around GBP109.9 million, up 15% on 2020 but 3% below 2019. Expects underlying profit to be in line with board expectations. Expects to reintroduce final dividend payment for 2021. Says is satisfied with trading performance in year and encouraged by start to 2022, though adds: "Whilst demand throughout the fluid power market has continued to recover, it is clear that it will be well into 2022, if not longer, before global supply chains for fluid power product return to pre pandemic levels of both consistency and breadth of supply. Good progress against our strategic objectives continues to enhance the group's medium term prospects. However, until supply is fully recovered, the board is more cautious in the short term outlook."

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
26 Mar 2024 14:00

Scancell doses first patient in melanoma-focused trials

(Alliance News) - Scancell Holdings PLC announced on Tuesday that the first patient of a new trial cohort has been dosed with its iSCIB1+ therapeutic.

Read more
5 Feb 2024 14:09

TRADING UPDATES: Alliance Pharma appoints chair; FireAngel sales down

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
30 Jan 2024 13:56

Scancell interim loss narrows amid finance gain on derivative

(Alliance News) - Scancell Holdings PLC on Tuesday reported a narrowed loss as it gained on the revaluation of derivative liability.

Read more
17 Jan 2024 14:26

IN BRIEF: Scancell approved by MHRA to add new cohort to Scope trial

Scancell Holdings PLC - Oxford, England-based developer of immunotherapies for treatment of cancer and infectious disease said - Receives approval from UK's Medicines & Healthcare products Regulatory agency to add a third cohort to the Scope trial. Says the cohort will consist of 43 melanoma patients who will receive iSCIB1+ with doublet therapy, consisting of ipilimumab, under the brand name Yervoy, plus nivolumab, under the name Opdivo. "Exceptional" results from the first 13 patients receiving SCIB1 in the ongoing Scope trial, with an objective response rate of 85%, indicate a high probability of success in this cohort, which is expected to complete in the second quarter of 2024. Meanwhile, recruitment into the iSCIB1+ cohort is expected to be complete by the end of the second quarter as well, with early data expected in the third quarter of 2024.

Read more
19 Dec 2023 13:35

Scancell raises GBP12 million in total from fundraise

(Alliance News) - Scancell Holdings PLC on Tuesday said it has raised GBP11.9 million in total, from an open offer, placing, and subscription of shares.

Read more
1 Dec 2023 09:54

IN BRIEF: Scancell raises GBP10.7 million in upsized share sale

Scancell Holdings PLC - Oxford, England-based developer of immunotherapies for treatment of cancer and infectious disease - Raises GBP10.7 million from the placing and subscription of 97.0 million new shares at 11 pence each. The placing is run by Stifel Nicolaus Europe Ltd and WG Partners LLP. Scancell also plans an open offer of shares at the same price to raise up to another GBP2.0 million. Scancell says the placing was oversubscribed and upsized as a result. After the London market close on Thursday, Scancell had announced plans to raise just GBP6 million in the placing. It says the raise was led by "new institutional and life science specialist investors".

Read more
30 Nov 2023 21:10

EARNINGS AND TRADING: Dispensa and SkinBioTherapeutics losses widen

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
28 Nov 2023 14:57

TRADING UPDATES: Scancell trial progresses; OptiBiotix inks new deal

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
22 Nov 2023 15:53

UK shareholder meetings calendar - next 7 days

Thursday 23 November 
abrdn UK Smaller Companies Growth Trust PLCAGM
Avation PLCAGM
Bradda Head Lithium LtdAGM
DX Group PLCAGM
Europa Oil & Gas Holdings PLCAGM
Fiske PLCAGM
JPMorgan UK Smaller Cos Investment Trust PLCAGM
Hotel Chocolat Group PLCAGM
Pacific Horizon Investment Trust PLCAGM
Pan African Resources PLCAGM
PZ Cussons PLCAGM
Rosslyn Data Technologies PLCAGM
Friday 24 November 
Base Resources LtdAGM
Cloudbreak Discovery PLCAGM
Esken LtdEGM re Esken Renewables disposal
Neometals LtdAGM
Sovereign Metals LtdAGM
Sylvania Platinum LtdAGM
Monday 27 November 
Chelverton Growth Trust PLCGM re voluntary liquidation
European Smaller Cos Trust PLCAGM
JPMorgan Global Emerging Markets Income Trust PLCAGM
Quadrise PLCAGM
Tribal Group PLCGM re cash offer by Tiger Bidco 1 Ltd
Tuesday 28 November 
Bluefield Solar Income Fund LtdAGM
London Finance & Investment Group PLCAGM
Nanoco Group PLCAGM
Oakley Capital Investments LtdAGM
Wednesday 29 November 
Artemis Resources LtdAGM
Aura Energy LtdAGM
Contango Holdings PLCAGM
CVS Group PLCAGM
Fidelity Asian Values PLCAGM
Ikigai Ventures LtdAGM
Panthera Resources PLCAGM
Reconstruction Capital II LtdAGM
Renishaw PLCAGM
RiverFort Global Opportunities PLCAGM
Sabien Technology Group PLCAGM
Scancell Holdings PLCAGM
Seeing Machines LtdAGM
SLF Realisation Fund LtdAGM
Target Healthcare REIT PLCAGM
Thor Energy PLCAGM
Transense Technologies PLCAGM
Vast Resources PLCAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
10 Nov 2023 11:14

IN BRIEF: Scancell shares up as presents "trailblazing" trial data

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Presents data from first stage of Phase 2 Scope trial at 20th International Congress of the Society for Melanoma Research on Thursday. Trial investigates Scancell's SCIB1 vaccination combined with checkpoint inhibitors in advanced melanoma. Company reported mid-September that SCIB1 combined with CPIs showed an 82% objective response rate. Scope trial is currently in its second stage. Scancell says on Friday that in Cohort 1 nine responses were achieved earlier than expected, and probability of second-stage success is around 90% based on current data.

Read more
31 Oct 2023 14:45

EARNINGS: Frontier IP chair to step down; "busy" Rosslyn narrows loss

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
20 Oct 2023 09:00

IN BRIEF: Scancell says needs more time to publish annual results

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Says auditor request additional time to complete standard audit of its results of financial year 2023 that ended on April 30. Cites unforeseen circumstances impacting the audit engagement team. Says audit is substantially complete without any material audit issues.

Read more
17 Oct 2023 15:43

UK earnings, trading statements calendar - next 7 days

Wednesday 18 October 
888 Holdings PLCTrading Statement
Antofagasta PLCTrading Statement
BHP Group LtdTrading Statement
Cirata PLCTrading Statement
Hochschild Mining PLCTrading Statement
Liontrust Asset Management PLCTrading Statement
Quilter PLCTrading Statement
Segro PLCTrading Statement
Sosandar PLCTrading Statement
Whitbread PLCHalf Year Results
Thursday 19 October 
AJ Bell PLCTrading Statement
Centamin PLCQ3 Results
Deliveroo PLCTrading Statement
Dunelm Group PLCTrading Statement
GB Group PLCTrading Statement
Gear4Music PLCHalf Year Results
Hargreaves Lansdown PLCTrading Statement
London Stock Exchange Group PLCTrading Statement
Man Group PLCTrading Statement
Mondi PLCTrading Statement
PensionBee Group PLCTrading Statement
Rathbones Group PLCTrading Statement
Relx PLCTrading Statement
Rentokil Initial PLCQ3 Results
Sabre Insurance Group PLCTrading Statement
Schroders PLCTrading Statement
St James's Place PLCTrading Statement
Friday 20 October 
Foxtons Group PLCTrading Statement
InterContinental Hotels Group PLCTrading Statement
Record PLCTrading Statement
Monday 23 October 
Shanta Gold LtdTrading Statement
South32 LtdTrading Statement
Tuesday 24 October 
Angling Direct PLCHalf Year Results
Anglo American PLCTrading Statement
Barclays PLCQ3 Results
Bunzl PLCTrading Statement
FD Technologies PLCHalf Year Results
Gattaca PLCFull Year Results
Petra Diamonds LtdQ1 Results
Scancell Holdings PLCFull Year Results
Softcat PLCFull Year Results
Travis Perkins PLCTrading Statement
Trifast PLCTrading Statement
WAG Payment Solutions PLCTrading Statement
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
22 Sep 2023 13:05

IN BRIEF: Oxford Technology 2 VCT asset value hurt by AIM share falls

Oxford Technology 2 VCT PLC - venture capital trust investing in quoted and unquoted technology companies - Net asset value of OT1 shares falls by 16% to 37.9 pence on August 31 from 45.3p on February 28. Similarly, NAV of OT2 shares falls to 20.5p from 25.1p, of OT3 shares to 23.6p from 33.7p, and of OT4 shares to 25.4p from 29.7p. No dividends are paid during the half year, nor are any shares bought back.

Read more
19 Sep 2023 14:32

Scancell celebrates "positive" clinical trial data for cancer vaccine

(Alliance News) - Scancell Holdings PLC shares surged on Tuesday after the company announced positive results from the phase 2 clinical trial of its SCIB1 treatment for advanced melanoma.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.